When was Curium founded?

Curium was founded in 2017 and raised its 1st funding round within a year of its incorporation.

Where is Curium located?

Curium is headquartered in Paris, France. It is registered at St. Louis, Missouri.

How many employees does Curium have?

As of Dec 31, 2022, the latest employee count at Curium is 842.

Is Curium a funded company?

Curium is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Jan 2017.

When was the latest funding round of Curium?

Curium's latest funding was a $***** Seed round on Jan 2017, with participation from 1 investor.

Where does Curium rank among its competitors?

Curium ranks 4th amongst 97 active competitors, of which 22 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Ionetix, which secured $30M in Feb, 2026.

Who are the top competitors of Curium?

Curium's top competitors include AC Immune, NorthStar Medical Radioisotopes and Ionetix. Among them, Ionetix secured the most recent funding round in February, 2026.

Curium - 2026 Company Profile, Team, Funding & Competitors

Company Details

Curium is formed through the union of IBA Molecular and Mallinckrodt Nuclear Medicine. It focuses on developing, manufacturing and supplying SPECT, PET and therapeutic radiopharmaceuticals. It has molybdenum facility, three SPECT facilities and many PET & SPECT radiopharmacies across the United States and Europe. It offers products such as generators, cold kits, hot products and auxiliary products used for diagnosis & treatment of the thyroid, lungs, liver, bones, brain, heart, glands, kidneys and joints. Its PET products include Fluorocholine, FDG-IBA, Farna FDG 3000, Neuraceq, DOPACIS & CISNAF. Its SPECT products include TC99 generator, oncology, lung, kidney, bone, CVS, thyroid imaging & therapeutics.

Website: curiumpharma.com
Social
Email ID: *****@curiumpharma.com
Phone Number: +1 **********
Registered Address: St. Louis, Missouri

Key Metrics

Founded Year

2017

Location

Paris, France

Stage

Seed

Latest Funding Round

Seed, Jan 2017, $*****

Investors

CapVest

Ranked

4^th among 97 active competitors

Employee Count

842 as on Dec 31, 2022

Investment & Acquisitions

NUCLEIS & 4 more

Similar Companies

AC Immune & 119 more

View Curium's full profile

Curium is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Mallinckrodt Nuclear Medicine, Llc CIN: 472088928 , United States, Active	Dec 31, 1999	-	541 (As on Dec 31, 2024)	-
CORIUM CONSULTING s.r.o. CIN: 04856368 , Czech Republic, Active	Feb 29, 2016	-	-

Curium has raised funding over 1 round. Its latest funding round was a Seed round on Jan 2017 for $*****. 1 investor participated in its latest round. Curium has 1 institutional investor.

Here is the list of recent funding rounds of Curium:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 2017	5462276	Seed	8503995	5439455	8589050	9423658

Access funding benchmarks and valuations. Sign up today!

View details of Curium's funding rounds and investors

Curium's employee count trend

Curium has 842 employees as of Dec 22. The total employee count is 96.0% more than what it was in Dec 21. Here is Curium's employee count trend over the years:

Uncover Curium's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Curium include AC Immune, NorthStar Medical Radioisotopes and Ionetix. Here is the list of Top 10 competitors of Curium, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	AC Immune 2003, Lausanne (Switzerland), Public	Developer of antibodies, small molecules, and vaccines for Alzheimer’s disease and other neurodegenerative diseases	$120M	BVF Partners, Dievini & 4 others	61/100
2nd	NorthStar Medical Radioisotopes 2006, Madison (United States), Series B	Provider of sourcing, purification, and separation technologies for the Nuclear Medicine market	$15.1M	Hendricks Holding, Stateline Angels & 4 others	57/100
3rd	Ionetix 2009, San Francisco (United States), Series C	Radiopharmaceutical solutions provider specializing in cyclotron technology and targeted alpha therapy	$61.1M	Lilly, Riverland Capital & 1 others	56/100
4th	Curium 2017, Paris (France), Seed	Specialty developer, manufacturer & distributor of radiopharmaceuticals	-	CapVest	55/100
5th	RadioMedix 2006, Houston (United States), Series A	Developer of targeted radiopharmaceuticals for cancer diagnosis and treatment	$40M	Military Health, Portland & 1 others	55/100
6th	Niowave 2005, Lansing (United States), Series A	Provider of devices and radioisotopes for nuclear imaging	$9.95M	SBIR, OSTI	54/100
7th	BioArctic 2003, Bromma (Sweden), Public	Developer of disease-modifying treatments for neurodegenerative diseases	-	EQT, EIC Fund & 1 others	53/100
8th	Telix Pharma 2015, Melbourne (Australia), Public	Developer of theranostic radiopharmaceuticals for imaging and treating cancer	-	China Grand Pharmaceutical and Healthcare	52/100
9th	ImaginAb 2007, Los Angeles (United States), Series C	Immune imaging technology for cancer and autoimmune disease management	$59.6M	Novartis, Adage Capital Management & 12 others	50/100
10th	Avid 2004, Philadelphia (United States), Acquired	Developer of molecular imaging agents for chronic disease diagnosis	$69.9M	AllianceBernstein, Alta Partners & 8 others	49/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Curium's competitors? Click here to see the top ones

Curium has not made any investments yet. Curium has made 5 acquisitions.

Here is the list of latest three $acquisitions:

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Apr 10, 2025	Acquisition	NUCLEIS	2017	Liege (Belgium)
Mar 28, 2025	Acquisition	Monrol	1995	Kuwait City (Kuwait)
Mar 03, 2020	Acquisition	Zevacor	2013	Dulles (United States)